52,000-square-foot corporate headquarters in San Diego with R&D and GMP manufacturing center to open in 2022
Builds on current capability at Artiva’s partner, GC LabCell’s facility in Republic of Korea
Custom-built GMP manufacturing center further expands Artiva’s leadership position in scaled, off-the-shelf NK and CAR-NK therapeutic manufacturing for treatment of solid and hematological cancers
SAN DIEGO, August 12, 2021 – Artiva Biotherapeutics, Inc., (“Artiva”) an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, today announced the expansion of the Company’s U.S. facilities in San Diego. The new 52,000-square-foot facility will include research and process development laboratories and a multi-suite custom-built Good Manufacturing Practices (GMP) manufacturing center to support NK and CAR-NK cell production for Artiva’s pipeline development and clinical trial supply. The new facility and capabilities will be in addition to Artiva’s continued research and GMP manufacturing at its partner GC LabCell’s state-of-the-art 300,000-square-foot Cell Center, which comprises research labs, process development labs, and a 50,000-square-foot GMP cell therapy manufacturing facility in the Republic of Korea.
“Artiva’s new San Diego R&D and manufacturing facility is an important element of the Company’s expansion and will support research and development for our evolving pipeline of optimized NK and CAR-NK cell therapies for the treatment of cancer,” said Peter Flynn, PhD, COO of Artiva. “The custom-built manufacturing center will produce clinical product and position Artiva for pivotal studies and potential commercial supply.”
